Skip to main content

Table 2 The proportion of monomer form of HuNb1-IgG4 under 25Ā ā„ƒ and 40Ā ā„ƒ

From: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Ā 

25Ā Ā°C

40Ā Ā°C

Monomer (%)

Aggregates (%)

Fragments (%)

Monomer (%)

Aggregates (%)

Fragments (%)

Day 0

88.98

10.50

0.52

88.98

10.50

0.52

Day 2

89.26

10.03

0.72

91.27

8.18

0.56

Day 4

90.18

9.74

0.08

88.91

10.65

0.44

Day 6

90.79

9.17

0.04

89.03

10.93

0.03

Day 8

91.24

8.71

0.06

88.58

10.34

1.08

Day 10

90.74

9.23

0.03

89.04

10.70

0.26